<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JACC Case Rep</journal-id><journal-id journal-id-type="iso-abbrev">JACC Case Rep</journal-id><journal-title-group><journal-title>JACC Case Reports</journal-title></journal-title-group><issn pub-type="epub">2666-0849</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39972702</article-id><article-id pub-id-type="pmc">PMC11862153</article-id><article-id pub-id-type="pii">S2666-0849(24)01012-X</article-id><article-id pub-id-type="doi">10.1016/j.jaccas.2024.102948</article-id><article-id pub-id-type="publisher-id">102948</article-id><article-categories><subj-group subj-group-type="heading"><subject>Heart Failure and Cardiomyopathies</subject><subj-group><subject>Clinical Case</subject></subj-group></subj-group></article-categories><title-group><article-title>Acute Systemic Sclerosis-Associated Cardiomyopathy That Improved With Glucocorticoids and Cyclophosphamide</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Gustafson</surname><given-names>Andrew A.</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Trinh</surname><given-names>Katherine V.</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Lomasney</surname><given-names>Jon W.</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Shah</surname><given-names>Sanjiv J.</given-names></name><degrees>MD</degrees><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Hinchcliff</surname><given-names>Monique E.</given-names></name><degrees>MD, MS</degrees><email>monique.hinchcliff@yale.edu</email><xref rid="aff5" ref-type="aff">e</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><aff id="aff1"><label>a</label>Northwestern University Feinberg School of Medicine, Division of Hospital Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA</aff><aff id="aff2"><label>b</label>Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA</aff><aff id="aff3"><label>c</label>Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA</aff><aff id="aff4"><label>d</label>Department of Medicine, Division of Cardiology, Northwestern University Feinberg School of Medicine Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA</aff><aff id="aff5"><label>e</label>Department of Internal Medicine, Section of Rheumatology, Allergy &#x00026; Immunology, Yale School of Medicine, New Haven, Connecticut, USA</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label><bold>Address for correspondence:</bold> Dr Monique Hinchcliff, Director of Clinical and Translational Research for Rheumatology, Allergy &#x00026; Immunology, Associate Professor of Medicine, Yale School of Medicine, Rheumatology, Allergy &#x00026; Immunology, 300 Cedar Street, The Anlyan Center, PO BOX 208031, New Haven, Connecticut 06520-8055, USA. <email>monique.hinchcliff@yale.edu</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>19</day><month>2</month><year>2025</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><day>19</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>19</day><month>2</month><year>2025</year></pub-date><volume>30</volume><issue>4</issue><elocation-id>102948</elocation-id><history><date date-type="received"><day>11</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>29</day><month>10</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0010"><sec><title>Background</title><p>Systemic sclerosis (SSc) cardiomyopathy has a prevalence of 7 to 39% and is associated with increased mortality. Despite this, little evidence informs SSc cardiomyopathy treatment.</p></sec><sec><title>Case Summary</title><p>We present a patient with diffuse cutaneous SSc with acute heart failure. Extensive workup supported a diagnosis of SSc myopericarditis, although endomyocardial biopsies were unrevealing. She received intravenous cyclophosphamide and glucocorticoids and achieved significant and prolonged recovery.</p></sec><sec><title>Discussion</title><p>Our patient presented with systolic dysfunction as opposed to diastolic dysfunction that is more typical in patients with SSc-cardiomyopathy. Endomyocardial biopsies lacked T-lymphocyte infiltration that may be due to sampling error because &#x0003e;17 samples are needed to diagnose myocarditis in &#x0003e;80% of cases.</p></sec></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical Abstract</title><fig id="undfig1" position="anchor"><graphic xlink:href="ga1"/></fig></abstract><kwd-group id="kwrds9010"><title>Key Words</title><kwd>cardiac MRI</kwd><kwd>cyclophosphamide</kwd><kwd>myocarditis</kwd><kwd>myopericarditis</kwd><kwd>scleroderma</kwd><kwd>systemic sclerosis</kwd></kwd-group></article-meta><def-list><title>Abbreviations and Acronyms</title><def-item><term id="kwrd0015">CYC</term><def><p>cyclophosphamide</p></def></def-item><def-item><term id="kwrd0025">GC</term><def><p>glucocorticoids</p></def></def-item><def-item><term id="kwrd0035">IV</term><def><p>intravenous</p></def></def-item><def-item><term id="kwrd0045">LVEF</term><def><p>left ventricular ejection fraction</p></def></def-item><def-item><term id="kwrd0055">MR</term><def><p>magnetic resonance</p></def></def-item><def-item><term id="kwrd0065">SSc</term><def><p>Systemic sclerosis</p></def></def-item></def-list></front><body><p id="p0010">A 29-year-old woman with diffuse cutaneous systemic sclerosis (SSc) complicated by precapillary pulmonary hypertension, interstitial lung disease treated with mycophenolate mofetil, and gastrointestinal involvement was admitted to our institution for hypoxemia and volume overload. Medical history included recent diagnosis of myopericarditis based upon cardiac magnetic resonance (MR) at an outside institution that was treated with tapering glucocorticoids (GC).<boxed-text id="dtbox1"><sec id="dtbox1sec1"><title>Take-Home Messages</title><p id="p0015"><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0020">In patients with diffuse cutaneous SSc in acute heart failure, cardiac magnetic resonance should be considered.</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0025">Endomyocardial biopsies often lack evidence of myopericarditis because the disease process is patchy not diffuse, and thus empiric treatment with glucocorticoids and CYC should be considered.</p></list-item></list></p></sec></boxed-text></p><p id="p0030">Workup at our hospital included chest computed tomography angiography that showed bilateral ground glass opacities, right upper lobe infiltrates, and no emboli. Transthoracic echocardiogram revealed global hypokinesis, left ventricular ejection fraction (LVEF) of 10%, pulmonary artery systolic pressure of 48&#x000a0;mm&#x000a0;Hg and right atrial pressure of 10&#x000a0;mm&#x000a0;Hg. The patient received intravenous (IV) diuretics, empiric vancomycin and piperacillin/tazobactam, and mycophenolate mofetil was held, given the concern for heart failure and pneumonia. Recurrent myopericarditis was suspected and IV methylprednisolone, 16&#x000a0;mg/d, was started. Antibiotics were discontinued subsequently, given the high probability that the chest infiltrates were edema rather than infection based on clinical course (eg, afebrile) and laboratory assessments (eg, negative respiratory pathogen panel and cultures). Cardiac MR demonstrated reduced biventricular function, 4-chamber dilation, LVEF of 11%, and focal late gadolinium enhancement in the subepicardial and midmyocardial muscle suggestive of myopericarditis (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1A</xref>). Right heart catheterization with endomyocardial biopsy was pursued to evaluate for autoimmune myopericarditis given her prior history and unrevealing infectious workup: right atrial pressure of 10&#x000a0;mm&#x000a0;Hg, mean pulmonary artery pressure of 39&#x000a0;mm&#x000a0;Hg, and pulmonary capillary wedge pressure of 16&#x000a0;mm&#x000a0;Hg, suggestive of mixed precapillary and postcapillary pulmonary hypertension. Five right ventricular endomyocardial biopsies demonstrated mild myocyte hypertrophy and hyaline arteriolosclerosis, but few inflammatory cells and no contraction band necrosis or fibrosis, results inconsistent with myocarditis (<xref rid="fig1" ref-type="fig">Figures&#x000a0;1B to 1D</xref>). Despite this, IV cyclophosphamide (CYC) 750&#x000a0;mg/m<sup>2</sup> was initiated for a presumptive diagnosis of SSc myopericarditis. After clinical improvement, the patient was discharged on a tapering dose of prednisone 15&#x000a0;mg/d. Two weeks later, she was rehospitalized for heart failure with similar cardiac MR findings but improved with IV diuresis and was discharged on a tapering dose of prednisone 10&#x000a0;mg/d. After 2&#x000a0;months, the patient underwent a planned admission for IV methylprednisolone 1 g/d for 3&#x000a0;days followed by IV CYC 170&#x000a0;mg/m<sup>2</sup> for myocarditis treatment. One month later, she received IV methylprednisolone 500&#x000a0;mg/d for 3&#x000a0;days followed by IV CYC 500&#x000a0;mg/m<sup>2</sup>. Cardiac MR then demonstrated a moderately dilated left ventricle, LVEF of 43%, normal myocardial stress perfusion, and improved enhancement. Transthoracic echocardiograms over the next 5 years revealed sustained improvement in biventricular function with LVEF of 30% to 40%. The patient had no further hospitalizations for heart failure during this time.<fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>Presumed SSc Myopericarditis</p><p>(A) Cardiac magnetic resonance showing short axis views of the patient's cardiac magnetic resonance with contrast. These images of short axis sections of the heart (basal to apical mid-myocardial segments) show evidence of prominent late gadolinium enhancement at the basal inferior septal insertion point (aqua arrows), which can occur in patients with RV strain. There is also prominent subepicardial delayed enhancement in the mid lateral to basal inferolateral walls (yellow arrows). Subepicardial LV myocardial enhancement is typically indicative of an inflammatory cause of cardiomyopathy (eg, myocarditis). (B to D) Cardiac histopathology (hematoxylin &#x00026; eosin, CD3, and CD20, respectively) that fails to show inflammation with adjacent myocyte necrosis that is typical for myocarditis. LV&#x000a0;=&#x000a0;left ventricle; RV&#x000a0;=&#x000a0;right ventricle.</p></caption><graphic xlink:href="gr1"/></fig></p><sec id="sec1"><title>Discussion</title><p id="p0035">Primary cardiac disease as a direct consequence of SSc, or SSc cardiomyopathy, can manifest as microvascular coronary disease, systolic dysfunction, diastolic dysfunction, myocarditis, myocardial fibrosis, arrythmias, pericardial disease, and/or valvular disease.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> SSc cardiomyopathy has a reported prevalence of 7% to 39% and is associated with increased mortality.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Despite this, little evidence is available to inform treatment of SSc cardiomyopathy. Herein, we present a patient with diffuse cutaneous SSc with acute heart failure. Extensive work-up supported a diagnosis of SSc myopericarditis. She received IV CYC and GC and achieved significant and prolonged recovery.</p><p id="p0040">Our case is notable for our patient&#x02019;s significant systolic dysfunction, the use of advanced imaging including cardiac MR for diagnosis, and our patient&#x02019;s sustained response to therapy. SSc cardiomyopathy often presents insidiously, more commonly with diastolic versus systolic dysfunction as noted in our patient.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> Results of a EUSTAR (European Scleroderma Trials and Research) study noted a prevalence of SSc myocarditis-associated reduced EF of 5.4%.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> Although the transthoracic echocardiogram remains a mainstay for detection, cardiac MR, particularly with novel parametric techniques such as T1 mapping, is useful for characterizing myocardial inflammation, fibrosis, and/or perfusion abnormalities.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> Definitive diagnosis of inflammatory cardiomyopathy can be made with endomyocardial biopsy, typically demonstrating T lymphocyte infiltration and myocyte necrosis that are uncharacteristic of coronary ischemia. We suspect that our patient&#x02019;s negative biopsy resulted from sampling error; Hauck et&#x000a0;al<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> found that &#x0003e;17 samples were needed to diagnose myocarditis in &#x0003e;80% of cases. Alternative inconclusive biopsy explanations include prior immune suppression or a noninflammatory etiology, yet cardiac MR findings and response to immunosuppression speak against this. Patients with myocardial fibrosis and progressive cardiac dysfunction may experience improved systolic function with moderate dose GC (&#x0003c;15&#x000a0;mg prednisone per day to be mindful of the potential for scleroderma renal crisis associated with high dose GC) and other agents.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> Previous myocarditis case reports have shown clinical and radiologic improvement with regimens including pulse dose GC, CYC, mycophenolate mofetil, or azathioprine.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> Despite her significant disease, IV GC and CYC resulted in lasting clinical and imaging improvement.</p></sec><sec id="sec2"><title>Conclusions</title><p id="p0045">We describe a young patient with severely reduced systolic function attributed to myopericarditis despite inconclusive endomyocardial biopsies. The case underscores the importance of multimodality imaging in diagnosis, characterization, and surveillance of SSc cardiomyopathy. A sustained response to immunosuppression treatment with prolonged follow-up is not reported elsewhere in the literature. This case adds to the growing body of evidence to guide treatment of SSc cardiomyopathy and myopericarditis.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Funding Support and Author Disclosures</title><p id="p0050">This work was supported by National Institute of Arthritis and Musculoskeletal and Skin Diseases grant [R01 AR073270] to Dr Hinchcliff; and National Heart, Lung and Blood Institute grant grants [U54 HL160273, NS R01 HL149423] to Dr Shah. Dr Hinchcliff has received consultancy fees from AbbVie and has received research grant support from Boehringer Ingelheim and Kadmon for investigator-initiated research projects; is a Scientific Advisory Board Member for the National Scleroderma Foundation; and has participated in clinical trials with Boehringer Ingelheim, AbbVie, Kadmon, Mitsubishi, Horizon, Emerald Health. Dr Shah has received research grants from AstraZeneca, Corvia, and Pfizer, and consulting fees from Abbott, Alleviant, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer-Ingelheim, Boston Scientific, Bristol Myers Squibb, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Imara, Impulse Dynamics, Intellia, Ionis, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sardocor, Shifamed, Tenax, Tenaya, and Ultromics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Giuca</surname><given-names>A.</given-names></name><name><surname>Gegenava</surname><given-names>T.</given-names></name><name><surname>Mihai</surname><given-names>C.M.</given-names></name><etal/></person-group><article-title>Sclerodermic cardiomyopathy-a state-of-the-art review</article-title><source>Diagnostics (Basel)</source><volume>12</volume><issue>3</issue><year>2022</year></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Bissell</surname><given-names>L.A.</given-names></name><name><surname>Md Yusof</surname><given-names>M.Y.</given-names></name><name><surname>Buch</surname><given-names>M.H.</given-names></name></person-group><article-title>Primary&#x000a0;myocardial disease in scleroderma: a comprehensive review of the literature to inform the UK Systemic Sclerosis Study Group cardiac working group</article-title><source>Rheumatology (Oxford)</source><volume>56</volume><year>2017</year><fpage>882</fpage><lpage>895</lpage><pub-id pub-id-type="pmid">27940590</pub-id>
</element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Allanore</surname><given-names>Y.</given-names></name><name><surname>Meune</surname><given-names>C.</given-names></name><name><surname>Vonk</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis</article-title><source>Ann Rheum Dis</source><volume>69</volume><year>2010</year><fpage>218</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">19279015</pub-id>
</element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Mavrogeni</surname><given-names>S.I.</given-names></name><name><surname>Bratis</surname><given-names>K.</given-names></name><name><surname>Karabela</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Cardiovascular magnetic resonance imaging clarifies cardiac pathophysiology in early, asymptomatic diffuse systemic sclerosis</article-title><source>Inflamm Allergy Drug Targets</source><volume>14</volume><year>2015</year><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">26374223</pub-id>
</element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Hauck</surname><given-names>A.J.</given-names></name><name><surname>Kearney</surname><given-names>D.L.</given-names></name><name><surname>Edwards</surname><given-names>W.D.</given-names></name></person-group><article-title>Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error</article-title><source>Mayo Clin Proc</source><volume>64</volume><year>1989</year><fpage>1235</fpage><lpage>1245</lpage><pub-id pub-id-type="pmid">2593714</pub-id>
</element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Bissell</surname><given-names>L.A.</given-names></name><name><surname>Anderson</surname><given-names>M.</given-names></name><name><surname>Burgess</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis</article-title><source>Rheumatology (Oxford)</source><volume>56</volume><year>2017</year><fpage>912</fpage><lpage>921</lpage><pub-id pub-id-type="pmid">28160468</pub-id>
</element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Mavrogeni</surname><given-names>S.</given-names></name><name><surname>Koutsogeorgopoulou</surname><given-names>L.</given-names></name><name><surname>Karabela</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Silent myocarditis in systemic sclerosis detected by cardiovascular magnetic resonance using Lake Louise criteria</article-title><source>BMC Cardiovasc Disord</source><volume>17</volume><year>2017</year><fpage>187</fpage><pub-id pub-id-type="pmid">28716007</pub-id>
</element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Pieroni</surname><given-names>M.</given-names></name><name><surname>De Santis</surname><given-names>M.</given-names></name><name><surname>Zizzo</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression</article-title><source>Semin Arthritis Rheum</source><volume>43</volume><year>2014</year><fpage>526</fpage><lpage>535</lpage><pub-id pub-id-type="pmid">23932313</pub-id>
</element-citation></ref></ref-list><fn-group><fn id="d36e23"><p id="ntpara0015aa">The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors&#x02019; institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the <ext-link ext-link-type="uri" xlink:href="https://www.jacc.org/author-center" id="interref1">Author Center</ext-link>.</p></fn></fn-group></back></article>